Advertisement


Rongbo Lin, MD, on Gastric Cancer: Results From the FNF-004 Trial

2019 Gastrointestinal Cancers Symposium

Advertisement

Rongbo Lin, MD, of Fujian Cancer Hospital, discusses phase II study findings on FOLFOX alone vs paclitaxel plus FOLFOX vs intraperitoneal paclitaxel plus FOLFOX as a first-line treatment in advanced gastric cancer (Abstract 6).



Related Videos

Hepatobiliary Cancer

Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib

Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses an analysis of survival and objective response in patients with hepatocellular carcinoma who took part in a phase III study of lenvatinib (Abstract 186).

Hepatobiliary Cancer

Heinz-Josef Lenz, MD, on BRAF V600E–Mutated Biliary Tract Cancer: Results From the ROAR Basket Trial

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E–mutated biliary tract cancer (Abstract 187).

Gastroesophageal Cancer
Immunotherapy

Takashi Kojima, MD, on Esophageal Cancer: Results From the KEYNOTE-181 Trial on Immunotherapy vs Chemotherapy

Takashi Kojima, MD, of the National Cancer Center Hospital East, discusses phase III study findings on pembrolizumab vs chemotherapy as second-line treatment for advanced esophageal cancer (Abstract 2).

Neuroendocrine Tumors
Immunotherapy

Jonathan R. Strosberg, MD, on Neuroendocrine Tumors: Results From the KEYNOTE-158 Trial on PD-1 Inhibition

Jonathan R. Strosberg, MD, of the Moffitt Cancer Center, discusses phase II study findings on pembrolizumab as a treatment for advanced neuroendocrine tumors (Abstract 190).

Gastrointestinal Cancer

David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy and safety of third-line trifluridine/tipiracil in patients with metastatic gastric cancer with or without prior gastrectomy (Abstract 3).

Advertisement

Advertisement




Advertisement